4

2 7 8 2 4 ( ) 8 : 0 0 9 : 3 0
: 3

1.
2.

( )

3
( )
4.

()
1
2-1
2 - 2
3 - 1
3 - 2
3-3
3 - 4
4-1
4-2
4-3
4 - 4

4
( )
( )


( P h R M A )
( E F P I A )




2 0 3 5

:27824()8:00 9:30
: 3

15

(90)

( 3 6 )

( P h R M A )
M S D

( E F P I A )

( )

(AMED)
(PMDA)

80%

8096

iPS

( )

()

( )

`1
;

()

M&A

(6 )

PMDA

2-2

(
)
27 8 24

2015

80%

()

(20 4 )

=
(2013 :100 )

phrma Futllre,Ho 207.ml1 2014

"C
O n


O CIN
O iPS

(CIN) (

)

(NC)

()

iPSAMED

GMP 3

AMED PMDA

NC nfH

AMED PMDA .
24 26 1

Ju

()

()

!
h

O
O



1
0 80%

27
1 ()30

:LhEn A=

E Li
PMDA

2E

PIC/SGDP GDP

10

O
(6)
()

()

,3(lcH)
> :ASEAN:

> : 2

PMDA

0 5

i31 1

0 (
80% )

l

` M&A

12

80%
()

()

20

4
, _L]

13

( )

(2014 )
: $
50,000
45,000
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0

"::::::]:::!:::

17
:::
::::3;
,7

1
l

Pharma FutureJ

:
{)

15

(2013 : 100 )
:
6

:6

Phama Future,No.207,Mar 2014

P u b n s h e d b y C e O o d h Dsattraa t o o

16

30 (2014 )

12
2

,40

2
.LOTA'17
1 i[7

d7:t'\'t-

nfrvtsqr'i, mfr{tslrr, )r1t'-

"

7-
rt

4"0
]
rc',-^' rf,tgb'ta

"

copD/htf :--!?!'-'l

6.865

Dr

,:

;ET/ARB
7

UCB

"

3ttttt

7'vl'ttl,

ilt'tr*

7r1tt'-

177=j'

wrN^ae

lttu?,t^

rstr

"

7 7

"
4,8

,I:;r

;I
,'tt^"r,

rrrrro

4J6

3,7

3,460

:I
1
1
/1
'

4,237

i:1111_

' HER2 L _

4,464

':::!'

rB

3.2s2

X2
H/C
_

111:;,

:11

3,095

E
()

Phmm
:
Futtr
(20155)J

17

I=22 IFttf

"

4 26
(2007

3
(20034 30)

5
(2007 330)

(20071015)

,
5
(2012 66) .

1
"1 ,

5 2012
(2012 3 30 )

(2013 6 14 )

(2014 7 22 )

2013



J

, .'

( )
( : )
( :)

( )

( )

ICrr


2013

( 2013 )

nEH

E=================================

L _ _ _ _

0
=

(AMED)

()

PMDA
&

(MS)

IPS

== ====T

::

ili

: I

"

1=IF
1

1
L _ _ _

EI [

2014

( 2013.102014.9)

()
:GE
19=120

)

()020151MS Health,MIDAS,Market Segmentatlon

RX oniy(PRESCRI 10N80UND)

MAT Sep 2014,

23

2015 8 24

15 17
EIJ

> OTC
>

>
>

> =
>

>

s.

 2015

2015(

2015

180%

.
O 29 4



.
26


.

2015

(
1
)

2015

> 2014
> 80%

25%

(0 )

22% ?oE

22%

2009 2010 2011 2012 2013 2014

*1 lMS Baso JPM(

).1"
*2 " (0
3 70%"

" ()J

70% 80%

2014
3.0%
2.0%

1.8%
1.1%

1.0%

1.2%

0.0%
-1.0%
-2.0%
-3.0%
-4.0%

-4.2%

-5.0%

2011

20121E

41.500

42,000
(500)

20131EE

42,700
(700)

(22 :)
* :2010E E

201411=
401000
(Al,800)
9


"

"

= Lf
: " 58.9% -198.2% -34.1% 57.3% -44.8% 8-44.0%

10

2018 20201E
10001:`(80%)

12;l4+Etltltt.

2013 4 2018 3

(60% )

.l+fr.lf,Eilfro*st"

2015 72021 3

E*9r*uy4.ft*lt*]x

11

E

> =
> = 10GMP2
>
0

1
2

1998

9
7%

2000
7.0%

2002
6.3%

2004

4.2%

2006

6.7%

2003
5.2%

2010
5.75%

2012

2014

6.00%

2014 9 10

5.64

+2_90%)

12

>

>
>

()
rt (15LAn

E 0

 3-2

()

2015824

10

0 AMEDPMDA

1
(1)( I)
0

()
0

1.
(2)( I)
10
PS

NC

2 ( I)
0
7

3.
( I)

4.
0
27

5. ( )J

APAC(
)

1 11(10)/

1400

1200

1000

800

600

400

200

1995

2000

2005

2010

20004
)

20004 2-f r
20
" m = J r AIE

DATA B

K2015J

2011

2012

2013

0 ()

1600

>

>
(NC)

>

>

>

>

>

>

>

A
10

>

0
1
>

g
()

15HL4m
)

E

>

:
(2012)
10)
4 (APAC)(2015 49

//'

j nfnCt=au\(fl*frf=0oodSubmleelon
Praotloe
/l,f
t, t =I>nr. e1di'lt]ofr!|{bt=a66r5atofiTt=

< >

3
.

< / >

3-3

2015824
(PhRMA)

G7

2017

14

 PhRMA
AMED

PhRMA 2013

1.

2025

::::::lill>

3 8 19

'15 '16

17 '18

`19 '20

'21 '22

20252

0
Z2

'23 '24 '25(lF )

1 {b)1
}
*1 (a):2013E
(b):2014

*2 5%

IMS
:[FPIA

Z2 :

2.

innovattve Medicine inttiattve(lMD

(EFPIA)

EUC10 EFttA

(C10 )
1
1

02013 C33 IM12

7.000

IM
J 2

IMI

/
/ /

lMl

lT

()

Global CTD :

MRA

/MRBP

/

:

(

)

70%

50%

25%

:=
nt

___2010

10%

20%

260/
30%

40%

60%

0%
'13

'15

'17

'19

'21
15

'16

'17

'18

.19

'20

'21

'22

'23

'24

'25

1 g

2010
20255996

120062009

22021-2022

2 0 1 2 - 2 0 2 5

J:L
:EFP:AJlMS

IMI

_
10

Scientinc Research
Agenda

Annua!

Plan
Implementation

/EI

10

FP7: EU 7th FrameworkProgrammefor Research

lMi
:

()

"
:0 lL

II
]

"
1

:rt ,
"

,
nm

m
"

" , .
.

tm

ta '

o
ll

"
"
,'`

9
3
.

"

,
n

z,l7
7>y-7.lttJt

"

:"

= "
(coPo)

"

J an

*(2011

EFPIA apan 24
(2013)

EFPiAapan

EFP:Aapan
2 6 , 0 0 0
( )

1",lrfr

t(L)afl ./

,../

,
'

_ , 4
1 1 '

" Q

: 1
il,

2013 )

52

'

 4-1

27 824

SCRUM Japan

Muttp
x ( O n c O m i n e O C a n c e r R e s e a r c h P a
n d
)

LCSCRUM

Japan

NCC
SCRUM 3apan

EPOC
TR

GISCREEN

Japan

( l 1 )
ARTIS

SCRUM Japan

1)

SCRUM Japan

SCRUMJapanSRL GISCREENJapanThermo Fisher

iELC
O n c O m i n e O C a n c e r R e s e a r c h P a n d ( O CP
)
M u t t i p l e x

Gastric(31) 871an(22)
Chobn91o(7) Uterine{0)
Sarcoma(2)

Prechbn Med he

O NCC AMED etci

:ISOCLIACAP etc.
O MGC(MediCal Genome center)
0



( 161 )

the Geneuc lnfOrmaUon NondiscHminaUon Act(GINA)

=

($5
000/ )

 ()

4-2

(JR)
() (30)

1. (26 5 )

aHHE

1013' 7=] ( )
"

2. 0 30ha)

R (7 )

4.

3.

2.

DR

2DR

()

()
(
)DR
DR
DR
()

( )
( )

(Drug Ropositio
nD

 o
(hANP) ()( 1)
()( 2)

ll

_0-

l hANP

2015824

1.

2.

3.

1,2

4. ()

o ng
repos

NTD()

2 0 1 3 5 1 5

31

4.

0 t
0
0 `

V
>

>

M ,F J Z

2 6 ( 2 0 1 4 )

2014

i
:11

Md

()

'

H25

I125

"

l121

2 5

rl

'

ill:
Hta

u5

H25

nE

{';

+tlfr

*7r,)h

H 2 5

21

,
I
ir

H2a
HZa
{r
16i

{+l)

,
*;,1

,!

I
,

H2b
4'
Hzs
kl6
HT'

1 5,

h7t7

,r

( )

", :0

H26 :

"1 4'

H7

tsr5

*r7)a

.
7

52
:

1=

it!
I;-oyll

031 1 tl lr

14
`
31 1 r"li

"5 =

rir
63-0"rt

u5
&i\
Aza
H?5
H26
H?4
Hr5
l!!-D

()
H211 76

4 0

(201410 )

{K}

" ll

{N}

{())

frlUurnuEHt? (W)

13F bruary 2015

1 1 1

V:ETNAM

ry:itl:
41` j
:

1 12
1,1'1

j3ni
:11 4:1 1
tTo f
Hf
bll `
(1) (3) (4)

4 E

NHK

1 12 "

4 r
J " J
.
12

EJ

=
.

` "
t
.
1 l
F
J

IL
b Wi

i`4 .
0

ItlEEt)

IJD

(: IASEAN)E=

E==1

10m

"

-1

7-

L '

c
GI

1,T

E" " dE 'a

'H=t d .

8 f
fB.tOt'

3 17.
81 B 0 '

E t = a=t

tet1,.
""

mO"

<H

E E 0 lit
.t 'mt

:`1
a . .
.

0 E l.
Nu " L .Dtt
:0
0.
4L8 11 F PJu "
0

 4-4

4 J

CRO

CRO

CRO

( )


.

sclel

&

0





WHO (NCD)
NCD( 60% )
l

2035

2035




2 0

2035 () 20


2035

GOAL

PRINCIPLES
:

( ,

.
2035 E

(1) , ()


(2)



(3)

 3
(1)

(3)

2020

2020

( )

( )

2035

2035

()

(2)

2020

( :
)

2035
2035

(1)

( )

2020

2 0 3 5

(2)

lCT

2020

-2035

2020

, ( ID

2035

()

-2020

2035


(4)

(5)

(3)

()

2020

( 5 )
(Chief medical officer)

2035

: 'F
II

II _li

1255
,

IAPAN VIS:ON:
HEALTH CARE

2035

2035




2 0

2035

2 7 6
2 0 3 5

5
2.2035
6

6
(1) 2035

(2)2035 .

(3) (2015) . 8
(4)2035 . 9
3. ..

11
4.2035 3 .
,13
(1) J. 13
2) J. 13
.14
(3) , ..
5. . 15
6.2035 . 17
(1) J. 17
i) .17
1) .
, 20
(2) J. 23
1) . 23
m) .25
(3) J. 28
7.2035 . 31
(1) .3:

33
(2)
(3) .34
i) .34

34
) .

m) .36
(4) 36
3) .38
8 ,
41
42
..
() . 43

GOAL

11111::,1
r::

PRINCIPLES
:

()

1.

2035
20 .
2035

2.2035
(1) 2035


1

5 10
2020 2 2025
3

20

4

65 2035

20

2035

1 9
() 13
() 17 ( )

2 186 2020

2015 2010 GDP 2020

3 75 2025

.



2
035J

()
http://
ww mhlw go Jp/stf/Seisakunitsuite/bunya/hukushi_kaigo/kaigo_koureisha/chilkiho
ukatsu/
4
24

28(2016) l,761 43(2031)
53(2041) 11676
75
29(2017) 6574

http:ww8 cao go Jp/kourei/whitepaper/ 2012/zenbun/index html

 5
20 6
2035

2035


20 2035

(2)2035
2035
(
)

( 3 ) ( 2 0 1 5 )

Jamison DT et al Global hea!th 2035: a world oonverging within a generation Lancet
2013:382:1898-955
Christensen C, Grossman JH, wang J (2008) The innovator's prescriptioni a disruptive
solution for health care, New York, New York, USA: HcGrawHill

1 9 6 1

8 .

(
)

C
:[::

;
mcP :81
Flhn i

an
9m2
OE

3
GDP

Zf

http:// mhiw go jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000076442 pdf



:0
( )

2 0 3 5

11

(4)2035

NPO

1 Hashimoto H, Ikegami N. Shibuya K, Izumida N, Noguchi H, Yasunaga H, Hiyata

, AcuinM, Reich
R Cost oontainment and quality of care in apan: is there a tradeoff? Lancet
2011;378:1174-82
1 1

3.

i (
) 3
()

2035
(1)

(2)
(3)

LF

:L
i

11

4 . 2 0 3 5 3

2 0 3 5

3

12
( 1 )

( 3 )

2 0

( 2 ) J







13

1 2 ( 1 0 a n ) ,
13 0
mmission on Social Determinants of Health (2008) CIosing the gap in a goneration: health
equity through action on the social determinants of health Final RepOrt of the Commission
on Social Determinants of Health Ceneva, Worid llealth Organization

5.
3

(
)





2

( )







!4

(PDCA)

14

6 . 2 0 3 5
( 1 )
i )
2035


()

28



2035



15


( :OALY)

" 7 (5)(39

National Clinical Database
CD)16
NCD

( )

(ChooSing Wisely)

17














National Clinical Database

9596 ( 4,000 120)

17


PET



Choosing Wisely An initiative of the ABI Foundation
http://www choosingwisely org

1)
2035

( )


(
)









( )


ICT

18

19

20

1 0

"

( )
2 2

()

2 0 5 0 6 2
2 3

I C T


'

10 6

" ( 27
5 27 )

20


" ( 57 80 ) 5 5
1


2

20 ()
http:// mlit go jp/colmon/000135838 pdf

2 0 3 5
N P O

( 2 )
i )
2035

( :

)


N P O

2 0 3 5 1 6 0 2 4

( q u a l i t y o f d e a t h )

25



(e
HR)



OTC
26 27

( )

( a d v a n c e d i r e c t " e )
q u a l i t y o f d e a t h
( )

24
( 2 4 1 ) 2 0 3 5 1 6 6

li)
2 0 3 5






J

N P O



2 0 3 5
3 0

28

2 0 ()



( )





29

J

WHO 2040
2020
J

2035

(3) J
2 0 3 5
( )

( C e n t e r f o r H e a l t h P r o t e c t i o n a n d P r o m o t i o n )

( ) ( I H R ) 3 0



D R ) 3 2
A T ) " (
( D
N P O

z s C u t l e r D t . B e h a v i o r a lh e a l t h i n t e r v e n t i o n s :W h a t w o r k sa n d w h y ?l n : A n d e r s o n N AB, u l a t a oR A ,
C o h e nB , e d i t o r s . l ' l a t i o n a l R e s e a r c hC o u n c i l , C r i t i c a l P e r s p e c t i v e so n R a c i a l a n d E t h n i c
D i f f e r e n c e s i n H e a l t h i n L a t e r L i f e . f l a s h i n g t o n ,D C : T h e l , l a t i o n a lA c a d e n i e sP r e s s ; 2 0 0 4 .
C o m i t t e e o n P o p u l a t i o n , D i v i s i o n o f B e h a v i o r a la n d S o c i a l S c i e n c e sa n d E d u c a t i o n .

]
:

G7

"

()

W140



ODA
( 2% 20% )WH0










(
)

IT

33




3 3

.2035
3 20

(
)

(AMED)
(
)
DA)
(P

(1)

PMDA

( 2 )
2 0 3 5 l C T

lCT

( N D B )

( K D B )

()

_
D P C 3 4
HDN2035(HealthCare Data Network

2 0 3 5 ) ( ) K D B N D B
I D ( )




N C D 2 0 3 5
N C D D P C
N D B K D B
Act)35
H I P A A ( H e a l t h l n s u r a n c e P o r t a b i l i t y a n d A c c o u n t a b i l i t y

(3)


2020 75 2021

1
()
()
" 1996
2003

i)


36


it)
i)
3 6

38

m)
2035
lCT

39




( )
(
40
)
(4)

( )

3 7

37

(2 )
Kik
http:/
w lw go Jp/file/05-Shingikal-12201
0-Shakalengokyokushougalhokenfukushibu

a
L

"

11
191
FttL
`
11
ttli

00C iCT

M a s s i v o o p e n o n l i n e c o u r s e s

(
)

42

()


(5)
,

90
110

()

NPO

()

(
)

2035

ICT

ID

(
)

2035

( :

(

)

44

( C h i e f
e d i c a 1 0 f f i c e r )

( 5 )

1 1 1

2035
,APAN VIS!ON:
H[ALTH CARE

2035

2035

2035

2 0

httD:// rnhlw go iplhealthcare2035

cOpynght OHealth Care 2035'Advisory Pane: All Rlghls Reserved

:4
=

111111111

1111

()

PRINCIPLES

2035

()
E l

HEALTHCARE

(
)

DESIGN

HEALTH LEADER

()

1.

(
)

2.
lD

(
)

_____

4.

3.

5.

(CMO)

8
r

2ol]kls(+Et t&#aotl

50 ()
130
2

= T

Ftta

6 5 ( )
1 4 5
2 0

48 ()1 23
20

tE

]
:

255

11

27 2 27 6 8 8 http:
.mhlw.go.jp/heaKhcare2035
: ( )

CEO

()

( )